{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:46:03Z","timestamp":1790754363144,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1245\/s10434-019-07597-0","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T15:02:50Z","timestamp":1563980570000},"page":"3374-3379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Axillary Pathologic Complete Response in Inflammatory Breast Cancer Patients: Implications for SLNB?"],"prefix":"10.1245","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7801-5371","authenticated-orcid":false,"given":"Folasade O.","family":"Imeokparia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasha M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesly A.","family":"Dossett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline S.","family":"Jeruss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred E.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Sabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"7597_CR1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927\u2013933.","journal-title":"Lancet Oncol."},{"key":"7597_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/SLA.0b013e3181c0e92a","volume":"251","author":"U Veronesi","year":"2010","unstructured":"Veronesi U, Giuseppe V, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595\u2013600.","journal-title":"Ann Surg."},{"key":"7597_CR3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","volume":"252","author":"AE Giuliano","year":"2010","unstructured":"Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426\u2013432.","journal-title":"Ann Surg."},{"issue":"2","key":"7597_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","volume":"17","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17(2):460\u2013469.","journal-title":"J Clin Oncol."},{"issue":"4","key":"7597_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","volume":"268","author":"OM Fayanju","year":"2018","unstructured":"Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018; 268(4):591\u2013601.","journal-title":"Ann Surg."},{"issue":"8","key":"7597_CR6","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275\u20131281.","journal-title":"J Clin Oncol."},{"key":"7597_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathologic complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384:164\u2013167.","journal-title":"Lancet."},{"issue":"15","key":"7597_CR8","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Biohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30(15):1796\u20131804.","journal-title":"J Clin Oncol."},{"key":"7597_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s002800050664","volume":"40","author":"NT Ueno","year":"1997","unstructured":"Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment in inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40:321\u2013329.","journal-title":"Cancer Chemother Pharmacol."},{"key":"7597_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3816\/CBC.2004.n.004","volume":"4","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004;4:415\u2013419.","journal-title":"Clin Breast Cancer."},{"key":"7597_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Young-Hyuck I, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advance, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicenter, open label, phase 2 trial. Lancet Oncol. 2012;13:25\u201332.","journal-title":"Lancet Oncol."},{"key":"7597_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Young-Hyuck I, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17:791\u2013800.","journal-title":"Lancet Oncol."},{"key":"7597_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1159\/000494264","volume":"11","author":"L Ogawa","year":"2018","unstructured":"Ogawa L, Lindquist D. Dual HER2 Suppression with lapatinib plus trastuzumab for metastatic inflammatory breast cancer: a case report of prolonged stable disease. Case Rep Oncol. 2018;11:855\u2013860.","journal-title":"Case Rep Oncol."},{"key":"7597_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/annonc\/mdq345","volume":"22","author":"S Dawood","year":"2011","unstructured":"Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22:515\u2013523.","journal-title":"Ann Oncol."},{"issue":"3","key":"7597_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF02573060","volume":"9","author":"V Stearns","year":"2002","unstructured":"Stearns V, Ewing CA, Slack R, et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002;9(3):235\u2013242.","journal-title":"Ann Surg Oncol."},{"key":"7597_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijsu.2009.04.012","volume":"7","author":"S Hidar","year":"2009","unstructured":"Hidar S, Bibi M, Gharbi O, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg. 2009;7:272\u2013275.","journal-title":"Int J Surg."},{"key":"7597_CR17","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072\u20131078.","journal-title":"J Clin Oncol."},{"issue":"14","key":"7597_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 clinical trial. JAMA. 2013;310(14):1455\u20131461.","journal-title":"JAMA"},{"key":"7597_CR19","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1245\/s10434-018-6637-9","volume":"25","author":"TT Nguyen","year":"2018","unstructured":"Nguyen TT, Hoskin TL, Day CN, et al. Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Onc. 2018;25:2596\u20132602.","journal-title":"Ann Surg Onc."},{"key":"7597_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00432-016-2281-6","volume":"143","author":"J Liu","year":"2017","unstructured":"Liu J, Chen K, Jiang W, et al. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. J Cancer Res Clin Oncol. 2017;143:161\u2013168.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"4","key":"7597_CR21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ASCOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260(4):608\u2013616.","journal-title":"Ann Surg."},{"issue":"7","key":"7597_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u2013618.","journal-title":"Lancet Oncol."},{"issue":"3","key":"7597_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC Study. J Clin Oncol. 2015;33(3):258\u2013264.","journal-title":"J Clin Oncol."},{"issue":"11","key":"7597_CR24","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, et. al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467\u20133474.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"7597_CR25","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.clbc.2017.06.014","volume":"18","author":"SM DeSnyder","year":"2018","unstructured":"DeSnyder SM, Mittendorf EA, Le-Petross C, et al. Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer. Clin Breast Cancer. 2018;18(1):e73\u2013e77.","journal-title":"Clin Breast Cancer."},{"issue":"10","key":"7597_CR26","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1245\/ASO.2003.03.073","volume":"10","author":"DN Krag","year":"2003","unstructured":"Krag DN and Single RM. Breast cancer survival according to number of nodes removed. Ann Surg Oncol. 2003;10(10):1152\u20131159.","journal-title":"Ann Surg Oncol."},{"issue":"18","key":"7597_CR27","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2008.19.5750","volume":"27","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27(18):2946\u20132953.","journal-title":"J Clin Oncol."},{"issue":"6","key":"7597_CR28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u2013575.","journal-title":"JAMA."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07597-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07597-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07597-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T13:47:12Z","timestamp":1664027232000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07597-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["7597"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07597-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"14 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no disclosures of any commercial interest in the subject of study or relevant financial or material support.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}